Engineering Immune Power Inside the Body

At GenCART, we are seeking to develop in-vivo CAR-T strategies as a novel alternative to the current ex vivo, retroviral or lentiviral gene-transfer paradigm. Rather than harvesting T cells from the patient and engineering them in the laboratory, in-vivo strategy delivers genetic instructions directly into the patient’s body, causing endogenous T cells to express CARs in situ.

This paradigm shift offers multiple compelling advantages:

• Elimination of apheresis and ex vivo manufacturing — In vivo CAR-T removes the need for cell collection, isolation, transduction, expansion, and reinfusion, thereby simplifying logistics, reducing time delays, and lowering dependence on centralized manufacturing capacity.
• Faster, more accessible therapy delivery — Without weeks of cell processing, patients may receive treatment more rapidly and in more distributed clinical settings, improving equity of access.
• Cost reduction and resource efficiencies — By collapsing multiple manufacturing steps into in vivo administration, the overall cost and infrastructure burden may be substantially reduced. 
• Controlled and modular delivery — We are exploring both viral and non-viral nanocarrier systems to deliver CAR-encoding nucleic acids selectively to T cells or immune compartments in vivo, with temporal and tissue-specific regulation. 
• Potential safety benefits in kinetics of CAR induction — In vivo expression may generate a more gradual CAR-bearing T-cell expansion rather than bolus infusion of fully armed cells, which could help moderate acute inflammatory responses (cytokine release syndrome) and improve tolerability.

We believe that in vivo CAR-T holds the potential to complement conventional ex vivo CAR-T manufacturing in the future—bringing safer, more scalable, and more democratized immune therapies to patients worldwide.